News & Updates
Excerpt from the Press Release: KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this…
Read More
Charity Blood Cancer UK has teamed up with oncology company RareCan to support the organisation’s delivery of clinical trials focussed on the prevention, diagnosis, or treatment of rare cancers. Excerpt from the Press Release: Blood cancer The partnership will see Blood Cancer UK join the charity network GIST Cancer UK as RareCan’s partner. The aim…
Read More
– The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs – BridgeBio and Helsinn have also established a non-exclusive framework agreement to identify and potentially co-develop and co-commercialize additional small molecule targeted oncology therapies – This framework agreement leverages BridgeBio’s…
Read More
The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors Excerpt from the Press Release: NEWARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that the first patient…
Read More
SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model Company also participates as new Crohn’s & Colitis Foundation Corporate Circle member to support Foundation’s IBD treatment, awareness and patient engagement initiatives Excerpt from the Press Release: BRISBANE, Calif. – November 18,…
Read More
Adam Miller, MD, to Serve as Lead Investigator for the First Randomized, Placebo Controlled Trial of CCR5 Antagonists and Statins for Chronic COVID Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–IncellDx’s Chronic COVID Treatment Center (CCTC) (www.covidlonghaulers.com) and ARISE™ MD Integrative Medicine & Surgery announced today a new partnership to evaluate CCR5 antagonists and…
Read More
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Nov. 18, 2021– Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology. (instead of CNSide detected CSF tumor cells…
Read More
Excerpt from the Press Release: MADISON, Wis. and PHILADELPHIA, Nov. 18, 2021 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS) today announced an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test. This unique effort will engage primary care and specialty providers, care coordinators, and patients from diverse populations across the Jefferson enterprise in research that aims…
Read More
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further evaluation in global registrational study expected to be initiated in 2022 following recent meeting to discuss trial design with U.S. and European regulators Excerpt from the Press Release:…
Read More
Primary endpoint data expected in Q1 2022 SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the completion of patient enrollment in its potentially pivotal study to evaluate the safety and efficacy of BT-001 for the…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?